Organization
SAES Getters SpA
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
SAES Getters SpA
... (3%), pneumonia (3%), major hemorrhage (3%), and actinic keratosis (3%). Serious AEs (SAEs) were seen in 22 patients (33%), with events in five patients (7%) ...
... repeated administrations in the trial. There have been 17 serious adverse events (SAEs) reported, of which nine were reported to be not related or unlikely ...
... (3%), pneumonia (3%), major hemorrhage (3%), and actinic keratosis (3%). Serious AEs (SAEs) were seen in 22 patients (33%), with events in five patients (7%) ...
... confidence interval (CI) 0.41-1.07] and significantly lower rates of serious adverse events (SAEs) [7.1% vs 13.1%; OR 0.51, 95% CI 0.32-0.81] in patients treated with ...
... to placebo, based upon hospitalizations and deaths designated as serious adverse events (SAEs) within 28 days after last dose of study drug. A similar finding ...
... characterized as possibly or probably related to LentiGlobin. Nine serious adverse events (SAEs) were reported, including two episodes of veno-occlusive liver disease; none were considered ...
... mobility solutions for millions of people, noted Lindsay Brooke, Editor in Chief. SAEs Autonomous Vehicle Engineering (AVE) magazine will deliver informed reporting and expert analysis ...
... 1.5x1012 CFU for 14 days. There have been no serious adverse events (SAEs), and no cases of infection with the bacteria in this study. While ...
... and infusion-related reactions (IRRs). The frequency of deaths and serious adverse events (SAEs) was similar in the patisiran and placebo groups. These data support the ...
... and infusion-related reactions (IRRs). The frequency of deaths and serious adverse events (SAEs) was similar in the patisiran and placebo groups. These data support the ...
Subscribe now for full coverage on SAES Getters SpA
Start My Free Trial